Abstract
Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis using prospective multi-institutional trials. We review and update the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, and its possible extension of use to operable patients, from the perspectives of an experienced radiation oncologist and a thoracic surgeon.
Original language | English (US) |
---|---|
Pages (from-to) | 8-13 |
Number of pages | 6 |
Journal | Seminars in thoracic and cardiovascular surgery |
Volume | 25 |
Issue number | 1 |
DOIs | |
State | Published - 2013 |
Keywords
- Early stage
- Non-small cell lung cancer
- Operable
- SABR
- SBRT
- Stereotactic ablative radiotherapy
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine